Key facts
- This page summarizes Jonathan Rubin's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Jan 2025, 17:01.
Jonathan Rubin - 28 Jan 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- SUPN
- Reported as of
- 28 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jan 2025, 17:01:18 UTC
- Prior SEC filing
- 30 Dec 2024
- Next SEC filing
- 21 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Rubin filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 29 Jan 2025.
Change
- Previous filing in this sequence was filed on 30 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,905
- Date
- 28 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Performance Share Units
Award
- Transaction value
- $0
- Shares
- +1,875
- Change %
- Price
- $0.000000
- Shares after
- 1,875
- Date
- 28 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,875
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes an aggregate of 310 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
Footnote F2
On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.